RBC Capital lowered the firm’s price target on Chemed (CHE) to $633 from $697 and keeps an Outperform rating on the shares after its Q3 earnings. The company delivered solid results with VITAS strength largely offsetting continued Roto-Rooter headwinds, and the firm was also encouraged to see census momentum continue, bolstered by strong hiring, the analyst tells investors in a research note. RBC adds however that its price target cut reflects a roll in its valuation model to next year’s estimates.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue